Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.
Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the study's location.SummaryDifference1%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedSeveral links related to thyroid cancer and neuroendocrine tumors have been removed, including resources from MedlinePlus and Dailymed, which may impact access to important medical information.SummaryDifference3%
- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedThe website has been updated to version 2.12.2, adding numerous resources related to thyroid cancer and neuroendocrine tumors, including links to MedlinePlus, DailyMed, and clinical trial documents.SummaryDifference3%
- Check37 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.0%
- Check44 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential improvements or features.SummaryDifference0.1%
- Check66 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.0%
Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.